Tau protein as a biomarker for asphyxia: A possible forensic tool?  by Salama, Mohamed & Mohamed, Wael M.Y.
Applied & Translational Genomics 9 (2016) 20–22
Contents lists available at ScienceDirect
Applied & Translational Genomics
j ourna l homepage: www.e lsev ie r .com/ locate /atgTau protein as a biomarker for asphyxia: A possible forensic tool?Mohamed Salama a,⁎, Wael M.Y. Mohamed b,c
a Forensic Medicine and Clinical Toxicology Department, Faculty of Medicine, Mansoura University, Egypt
b Clinical Pharmacology Department, Faculty of Medicine, Menouﬁa University, Egypt
c Basic Medical Science, Kulliyyah of Medicine, International Islamic University Malaysia, Kuantan, Pahang, Malaysia⁎ Corresponding author.
E-mail address: toxicsalama@hotmail.com (M. Salama
http://dx.doi.org/10.1016/j.atg.2016.03.001
2212-0661/© 2016 Published by Elsevier B.V. This is an oa b s t r a c ta r t i c l e i n f oArticle history:
Received 9 February 2016
Accepted 1 March 2016Asphyxial death has been a problem for forensic investigations due to the absence of a validated biomarker for
the diagnosis of this event. Recently, research on brain affection by asphyxia raised hopes on the possible use
of CNSmarkers for asphyxia. The cytoskeletal proteins seem to be attractive targets as they are vulnerable to hyp-
oxia and can be affected in asphyxial deaths. Tau, an important cytoskeletal protein, showed affection in many
neurodegenerative disorders and recently in some acute incidences like trauma and brain ischemia. In this report
we show the affection of the normal pattern of tau and pathological aggregates of tau in the case of brain hypoxia.
This may give new clues to asphyxial death investigations.





Asphyxia diagnosis is still challenging to forensic pathologists as
it is difﬁcult to separate hypoxic ischemic disease from agonal hyp-
oxia (Oehmichen et al., 2003). What makes this issue more puzzling
is that neuropathological examination shows nonspeciﬁc ﬁndings
(Kühn et al., 2005). It is important to ﬁnd relevant biological markers
to diagnose permanent hypoxic ischemic insult of the brain
(Oehmichen et al., 2003). Brain death is the permanent end result
of hypoxic ischemia of the brain. It is associated with brain edema,
absence of vital reaction, herniation of the brain and softening of
the gray matter (Oehmichen, 1994). It is supposed that brain anoxia
and subsequent necrosis is a time dependent process although this
drastic insult does not involve all neurons at the same time. This hypoth-
esis is supported by the signs of vital reactions within the perivascular
tissue of the brain parenchyma (Oehmichen, 1994). Cytoskeletal protein
comprises a diverse group of proteins that maintain the structure and
function of CNS. Microtubule-associated proteins (MAPs), one of these
proteins, appear to be among the most sensitive of the cytoskeletal pro-
teins in response to brain hypoxia/anoxia. Therefore, these proteins, in-
cluding MAP2, are good sensitive markers for early agonal asphyxia
(Hirokawa, 1994; Johnson and Jope, 1992; Tucker, 1990). Experimental
studies on rats showed loss of MAP2 immunoreactivity in cases of rat
brain with hypoxia–ischemia (Kwei et al., 1993;Malinak and Silverstein,
1996; Ota et al., 1997). More recently, Tau – another cytoskeletal protein
– gained more attention due to its involvement in many neurodegener-
ative disorders. In normal brains, tau is thought to play an important role
in microtubule stabilization and assembly. Furthermore, taumay help in).
pen access article under the CC BY-Nsignal transduction mechanisms, interactions with the actin cytoskele-
ton, neurite outgrowth and stabilization during brain development
(Kambe et al., 2011). In brains of patients suffering from tauopathic dis-
ease, tau is found as aggregated abnormal ﬁlaments, such as neuroﬁbril-
lary tangles localized in the somatodendritic compartments of cells, in
contrast to their usual localization in axons. The distribution and ultra-
structural morphology of tangles in the brain differ according to speciﬁc
tauopathies and even to speciﬁc disease-causing mutations (Ludolph
et al., 2009). Although, tau aggregates have been linked to a group of
chronic neurodegenerative disorders, recent research correlated tau ag-
gregates to acute brain insult e.g. ischemia (Villamil-Ortiz and Cardona-
Gomez, 2015). The present study aimed to validate tau protein aggre-
gates as a biomarker for asphyxia. Since there are still no solid bio-
markers that can be used in forensic studies to assure diagnosis of
asphyxia, tau could be a helpful tool in pinpointing asphyxial death.
2. Materials and methods
2.1. Animal model of hypoxia–ischemia (HI)
Twentymice (C57/bl6) of both genders, 7 days old were used in this
study. Animals were purchased from the Medical Experimental Re-
search Center (MERC) of Mansoura University. All research was con-
ducted according to a protocol approved by the Medical Experimental
Research Center (MERC) of Mansoura University.
The HI group (10mice) was exposed to right common carotid artery
ligation on PND-7 under isoﬂurane anesthesia. Two hours after recov-
ery, mice were subjected to 8% O2 balanced with N2 for 20 min at
37 °C (Ten et al., 2003). Pups that have formed an experimental group
were returned to their dams. Control animals were considered as age-
and strain-matched naïve (no HI) mice.C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig 1. Image shows immunoﬂuorescent staining of the cerebral cortex in the control (left) and HI (right) groups against AT8 as a marker of tau protein.
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One day following the HI model, mice were deeply anaesthetized
and transcardially perfused with ice-cold 0.1 M phosphate buffered
saline (PBS) for 2 min. Thereafter, the brains were quickly removed,
post-ﬁxed in 4% paraformaldehyde at 4 °C for 48 h, and washed with
saline buffer. The brains were cut into 40-μm sections using a cryo-
stat (Leica, Wetzlar, Germany), collected in 10 regularly spaced se-
ries, and stored in 0.1 M PBS containing 0.01% (wt/vol) sodium
azide at 4 °C. Free-ﬂoating sections were stained with the mouse
monoclonal primary antibodies raised against anti-PHF Tau AT8 an-
tibody against pS202/pT205 (Thermo Scientiﬁc, Rockford, IL, USA;
ratio used was 1:100).
2.3. Image analysis
Stereological cell count was done by a blinded observer to the an-
imals' identity on regularly spaced (1/10) sections (average post-
processing thickness was 20 μm) under a 40× objective with the op-
tical fractionator method using the Stereo-Investigator software
(MicroBrightField, Inc., Williston, VT, USA) in the frontal and parietal
cortex of one hemisphere. The frontal cortex was analyzed between
1.94 and 0.86 mm anterior and 0 to 2.0 mm lateral from bregma,
and the parietal cortex between 1.1 and 2.3 mm posterior and 1.0
to 3.0 mm lateral from bregma. Coordinates were based on Paxinos
and Franklin (2012).
2.4. Statistical analysis
For statistical analysis we used GraphPad Prism 5.0 (La Jolla, CA,
USA). Results were expressed as mean ± SEM. A p-value b 0.05
was assumed to be statistically signiﬁcant. The experimental groups
were compared with a one-way analysis of variance (ANOVA) with
the Newman–Keuls post-hoc test, or two-way ANOVA followed by
a post-hoc least signiﬁcant difference (LSD) test, as appropriate.
3. Results
Analysis of tau aggregates 1 day after the HI model showed highly
signiﬁcant elevation compared to the control group as shown in Fig. 1
and Table 1.Table 1
AT8 IR cell count after 1 day of hypoxia.
Control group HI group
10,000 3.5 × 107⁎
⁎ P value b 0.001 compared to control group.4. Discussion
The present report shows evidence that abnormal tau aggregates
can be increased on exposure to hypoxia. These results build on the
known previous studies showing that following stroke 3:4 of patients
develop neurodegenerative disorders most commonly dementia and
Alzheimer's disease (Wen et al., 2004). Pathological studies after death
of these patients show typical AD characterizing pathology in the form
of beta-amyloid proteins and tau aggregates (Song et al., 2013). More
interesting pathophysiological studies of stroke showed abnormal
phosphorylation of tau protein in a pattern similar to chronic disorders
characterized by tauopathy (Cespedes-Rubio et al., 2010).
More recently, Villamil-Ortiz and Cardona-Gomez (2015) compared
the abnormal phosphorylation and aggregation pattern of tau in trans-
genicmice compared to the hypoxic–ischemicmicemodel. Their results
showed an acute rise in tau aggregates following ischemia in a pattern
comparable to the ﬁndings in old transgenic mice. The only difference
between the two groups was the rapid recovery of tauopathy in ische-
mic mice compared to the progressive course in the transgenic animals.
Our report conﬁrms the occurrence of abnormal tau aggregates in a
hypoxic model of mice. This change, which happens acutely, could be
a useful tool for forensic investigation of asphyxial death, as tau protein
would represent a unique and new biomarker for such event. Further-
more, from a clinical point of view, results from this study may have
considerable implications to other CNS insults e.g. TBI (Traumatic
Brain Injury). Tau may be used as a prognostic biomarker following
asphyxial incidents (Lv et al., 2015; Takahashi et al., 2014). In the previ-
ous works, tau was found to be elevated in CSF samples of neonatal as-
phyxia cases. This is in contrast to the ﬁndings of Liu et al. (2013) who
did not ﬁnd signiﬁcant elevation in serum levels of tau in similar
cases. This can be attributed to the fact that serum levels of cytoskeletal
proteins cannot be correlated to CNS injury due to early disappearance
by proteases, on the contrary using auto-antibodies would be more re-
liable method (Abou-Donia et al., 2013). Moreover, the involvement of
tau in the present study my extend its importance as a biomarker to
other brain injury and its related deaths e.g. heat induced brain damage
as in the work of Kibayashi and Shojo (2003). The involvement of tau
protein in asphyxial incidents may have great signiﬁcant implications
including: prognostication, therapeutic intervention, and delineating
potential treatment windows following such incidents. Overall, our
data provides a novel assessment for long termoutcomes after Ischemic
hypoxic brain insults.
4.1. Limitations
Despite the novelty and implications of this work, this study is not
without limitations. First, the current study used a small number of
mice of mixed sex without considering sex as a determining factor. An-
other limitation was that there were no neurobehavioral tests to assess
the neurofunctional outcomes in this study that makes it difﬁcult to
22 M. Salama, W.M.Y. Mohamed / Applied & Translational Genomics 9 (2016) 20–22know whether biological relationships among tau and other bio-
markers, are due to direct effects or simply epiphenomena derived
from other causal components of the secondary injury cascade. More
important, we need to know whether these ﬁndings are active vital
reaction or postmortem events. Thus, there is a need for future experi-
mental studies designed to elucidate biochemical interactions between
various biomarkers.
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